Download PDF
Arzneimittelforschung 2009; 59(9): 455-460
DOI: 10.1055/s-0031-1296425
Spasmolytics
Editio Cantor Verlag Aulendorf (Germany)

Pharmacokinetics of Isoxsuprine Hydrochloride Administered Orally and Intramuscularly to Female Healthy Volunteers

Antonio Marzo
1   I.P.A.S. SA, Ligornetto, (Switzerland)
,
Dario Zava
2   Istituto Lusofarmaco D’Italia S.p.A., Peschiera Borromeo, Milan, (Italy)
,
Katrin Coa
1   I.P.A.S. SA, Ligornetto, (Switzerland)
,
Lorenzo Dal Bo
1   I.P.A.S. SA, Ligornetto, (Switzerland)
,
Shefqet Ismaili
1   I.P.A.S. SA, Ligornetto, (Switzerland)
,
Simona Tavazzi
1   I.P.A.S. SA, Ligornetto, (Switzerland)
,
Vittorio Cantoni
2   Istituto Lusofarmaco D’Italia S.p.A., Peschiera Borromeo, Milan, (Italy)
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2011 (online)

    Permissions and Reprints

Abstract

Isoxsuprine (1-(4-hydroxyphenyl)-2-(1-methyl-2-phenoxyethylamino)-1-propanol, CAS 395-28-8) is a peripheral vasodilator that also stimulates betaadrenergic receptors. It causes a direct relaxation of vascular and uterine smooth muscles and produces positive inotropic and chronotropic effects. It is widely used to arrest premature labour and miscarriage. The aim of this trial was to investigate the pharmacokinetics of isoxsuprine hydrochloride administered orally to healthy young female volunteers as an extended-release formulation at the doses of 30, 60 and 90 mg compared to 10 mg by i. m. route. A randomised, crossover, four-period, multisequence, single-dose design was adopted. Plasma and urine concentrations of free and total isoxsuprine were evaluated by tandem mass spectrometry that reached a low quantification limit of 1 ng/ml. From plasma concentrations Cmax, tmax, AUC0–t, AUC0–∞, t1/2 and Vd and from urine concentration CUE0–24h were evaluated by the non-compartmental model.

The free drug was present only in plasma after i. m. route, whereas total isoxsuprine, namely the drug after an enzymatic hydrolysis of the conjugate form, was detected in all plasma and urine samples. The distribution volume of the free drug proved to be 2.5 times higher than that of total isoxsuprine, which indicates a good penetration of the free drug into tissue compartments. Oral absorption was evaluated from the p. o./i. m. percentualized ratio of AUC and CUE and proved to be on average around 51%, being linearly correlated with the three doses administered. The oral absorption proved to be sustained as expected from the zero-order kinetics of the drug release from the core of the extended-release formulation. This has justified different values of half-life that was on average 2.2 h after the i. m. route and around 10 h after the three oral doses. After isoxsuprine administration, both oral and i. m. routes, the heart rate increased from baseline during the 9 h monitoring period. This was an expected finding attributable to the stimulating activity of β-adrenergic receptors. The tolerability of isoxsuprine proved to be very good with all the four administrations performed.

Key words

CAS 395-28-8 - Isoxsuprine, intramuscular absorption, oral absorption, pharmacokinetics, urinary excretion - Peripheral vasodilator - Vasosuprina®
 

  • References

  • 1 Isoxsuprine hydrochloride Martindale. The Complete Drug Reference. 35th ed London: Pharmaceutical Press; 2007
    Search in Google Scholar
  • 2 Kaindl F, Samuels SS, Selman D, Shaftel H. A new vasodilating and antispasmodic agent: isoxsuprine hydrochloride. Angiology. 1959; Aug 10: 185-92
    CrossrefPubMedSearch in Google Scholar
  • 3 Di Perri T, Forconi S, Guerrini M, Pecchi S, Pieragalli D, Cappelli R et al. Influence of non-selective and selective beta adrenoceptor blockade on isoxsuprine-dependent hemodynamic and rheologic changes. Angiology. 1981; Apr 32: 257-65
    CrossrefPubMedSearch in Google Scholar
  • 4 Salimbeni A, Manghisi E, Ferni G, Fregnan GB. Drug latentiation of isoxsuprine: synthesis and preliminary pharmacological activities of four monoesters. Farmaco [Sci]. 1983; Nov 38: 904-10
    PubMedSearch in Google Scholar
  • 5 Cohn JN. Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation. 1973; Jul 48 (1) 5-8
    CrossrefPubMedSearch in Google Scholar
  • 6 Gozo EG, Yebes RB. Hemodynamic effects of isoxsuprine in cardiac failure. Chest. 1984; 86: 736-40
    CrossrefPubMedSearch in Google Scholar
  • 7 Lish PM, Dungan KW, Peters EL. A survey of the effects of isoxsuprine on nonvascular smooth muscle. J Pharmacol Exp Ther. 1960; Jun 129: 191-9
    PubMedSearch in Google Scholar
  • 8 Lish PM, Hillyard IW, Dungan KW. The uterine relaxant properties of isoxsuprine. J Pharmacol Exp Ther. 1960; Aug 129: 438-44
    PubMedSearch in Google Scholar
  • 9 Johnson WL, McGaugey Jr HS, Thornton Jr WN. Effect of certain smooth muscle depressants on isolated human myometrial tissues. Am J Obstet Gynecol. 1963; Jun 1 (86) 296-302
    PubMedSearch in Google Scholar
  • 10 Isoxsuprine hydrochloride. The Merck Index. 13th ed. Whitehouse Station (NJ): Merck & Co. Inc.; 2001
    Search in Google Scholar
  • 11 Koh KS. Premature labour. Can Med Assoc J. 1976; Apr 17: 700-7
    PubMedSearch in Google Scholar
  • 12 Calixto JB, Simas CM. Mechanism of action of isoprenaline, isoxsuprine, terbutaline and orciprenaline on gravid human isolated myometrium, Influence of the neuronal uptake process. Biol Reprod. 1984; Jun 30: 1117-23
    CrossrefPubMedSearch in Google Scholar
  • 13 Isoxsuprine hydrochloride. L’Informatore Farmaceutico. 25th ed. Milan (Italy): Elsevier Masson s.r.l.; 2008
    Search in Google Scholar
  • 14 Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98; July 2001
    PubMedSearch in Google Scholar